US2022133776A1PendingUtilityA1
Composition including glucosaminoglycan derivative and chemokine receptor activity regulator
Est. expiryMay 29, 2035(~8.8 yrs left)· nominal 20-yr term from priority
A61K 31/5375A61K 31/17A61K 45/00A61K 45/06A61K 31/728A61P 27/02A61K 31/216A61K 47/36A61K 9/0048A61K 47/61A61K 31/726A61K 47/50
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided are a composition comprising a GAG derivative and a chemokine receptor activity regulator, and a pharmaceutical composition comprising said composition.
Claims
exact text as granted — not AI-modified1 . A composition comprising a glycosaminoglycan derivative and a chemokine receptor activity regulator.
2 . The composition according to claim 1 , wherein the glycosaminoglycan derivative is a hydrophobic group-introduced glycosaminoglycan.
3 . The composition according to claim 1 , wherein the glycosaminoglycan derivative is a crosslinked glycosaminoglycan.
4 . The composition according to claim 1 , which comprises a covalent complex of the glycosaminoglycan derivative and the chemokine receptor activity regulator.
5 . The composition according to claim 1 , wherein the glycosaminoglycan derivative is a derivative of hyaluronic acid or chondroitin sulfate.
6 . The composition according to claim 1 , wherein the chemokine receptor activity regulator is a chemokine receptor antagonist.
7 . A pharmaceutical composition comprising the composition of claim 1 .
8 . The pharmaceutical composition according to claim 7 , which is a drug for treating a posterior eye disease.Join the waitlist — get patent alerts
Track US2022133776A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.